Nebulized Lidocaine, Dexmedetomedine and Their Combination in Direct Laryngoscopy Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 12, 2020

Primary Completion Date

July 11, 2021

Study Completion Date

July 11, 2021

Conditions
Hemodynamic Instability
Interventions
DRUG

Nebulized Lidocaine

will receive nebulized lidocaine 2%, 1 mg/kg with a maximum dose of 100 mg (5 ml).

DRUG

Nebulized dexmedetomidine

will receive nebulized dexmedetomidine (1 μg/kg diluted in 5 ml of saline 0.9%).

DRUG

Nebulized lidocaine and dexmedetomidine

will receive nebulized lidocaine 2% (0.5 mg/kg) and dexmedetomidine 0.5 μg/kg dexmedetomidine in 5 ml of saline 0.9%.

OTHER

Placebo

will receive nebulized saline 0.9% (5 ml) as control group.

Trial Locations (2)

11566

Ain Shams University, Cairo

11588

Ain Shams University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT04659057 - Nebulized Lidocaine, Dexmedetomedine and Their Combination in Direct Laryngoscopy Surgery | Biotech Hunter | Biotech Hunter